Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL244752 | 0.81 | ALDH1A1 (0.73) | ALDH1A1MAPTNPC1RAB9AHPGD | |
| SCHEMBL3434838 | 0.80 | ALDH1A1 (0.53) | ALDH1A1GAAMAPK1MAPTNPC1 | |
| SCHEMBL6985283 | 0.80 | ALDH1A1 (0.53) | ALDH1A1GAAMAPK1MAPTNPC1 | |
| Hydrochloric Acid SCHEMBL8114168 | 0.80 | ALDH1A1 (0.71) | ALDH1A1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL10049913 | 0.80 | NPC1 (0.54) | ALDH1A1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL10532167 | 0.80 | ALDH1A1 (0.49) | ALDH1A1GAAMAPK1MAPTNPC1 | |
| SCHEMBL10532170 | 0.80 | ALDH1A1 (0.57) | ALDH1A1GAAMAPK1MAPTNPC1 | |
| SCHEMBL8574686 | 0.79 | KDM4E (0.48) | ALDH1A1GAAMAPK1MAPTKMT2A | |
| SCHEMBL8146643 | 0.79 | KDM4E (0.48) | ALDH1A1GAAMAPK1MAPTKMT2A | |
| SCHEMBL20911243 | 0.78 | ALDH1A1 (0.76) | ALDH1A1GAAMAPK1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4288362-A | Monoazo pigments containing a quinazo linonylacetoacetanilide coupling component | BAYER AKTIENGESELLSCHAFT (DE) | 1981-09-08 | — | — | US | claimed |
| US-12545654-B2 | MYC inhibitors and uses thereof | STEMSYNERGY THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4578451-A2 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| EP-4214210-B1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | NOVARTIS AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2025-03-13 | — | — | US | disclosed |
| CN-119421877-A | Substituted heterocyclic compounds as HSET inhibitors | 默克专利股份公司 | 2025-02-11 | — | — | CN | disclosed |
| EP-4463444-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | Merck Patent GmbH (DE) | 2024-11-20 | — | — | EP | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-4988698-A | Cardiovascular disorders, hypotensive agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-29 | — | — | US | disclosed |
| CN-1042905-A | The preparation method of 2 (1H) quinolinone compounds and medicinal compositions thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1990-06-13 | — | — | CN | disclosed |
| EP-0370381-A2 | 2(1H)-quinolinone compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-30 | — | — | EP | disclosed |
| US-4421601-A | LACQUERS, INKS, PAINTS, TEXTILES, PAPER | BAYER AKTIENGESELLSCHAFT (DE) | 1983-12-20 | — | — | US | disclosed |
| US-4288362-A | Monoazo pigments containing a quinazo linonylacetoacetanilide coupling component | BAYER AKTIENGESELLSCHAFT (DE) | 1981-09-08 | — | — | US | disclosed |
| US-4260540-A | SPIN DYEING POLYACRYLONITRILE | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-07 | — | — | US | disclosed |
| US-4246401-A | Axomethine pigments | BAYER AKTIENGESELLSCHAFT (DE) | 1981-01-20 | — | — | US | disclosed |
| US-4225489-A | Heterocyclic azo dyes and pigments containing 4-quinazolinone moieties | BAYER AKTIENGESELLSCHAFT (DE) | 1980-09-30 | — | — | US | disclosed |
| US-4118185-A | FASTNESS, DEEP COLORS, AZO DYES, THIAZOLE DYES, PYRIDINE DYES | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
| US-4014863-A | LACQUERS, PRINTING INKS, PAINTS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | ALDH1A1 3565/4885GAA 2507/4885MAPK1 1689/4885 |
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | VHL, CDKN1A, CCNI | ALDH1A1 1680/4885GAA 1328/4885MAPK1 577/4885 |
| US-12545654-B2 | MYC inhibitors and uses thereof | MYC, MYCBP, NR2E1 | ALDH1A1 4317/4885GAA 4531/4885MAPK1 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.